Alvotech

Alvotech reported Q2 2026 revenue of $106 million and adjusted EPS of -$0.054, missing consensus estimates (revenue forecast $111.5 million; EPS -$0.0368). Production interruptions due to modernization work in Reykjavik weighed on sales; production had returned to planned levels by the end of the quarter. The FDA inspection concluded with a VAI classification. The company reconfirmed its full-year guidance (revenue $650–700 million, adjusted EBITDA $180–220 million) and expects a strong Q4; cash of $143 million and net debt of about $1.46 billion. Margins remained under pressure (Q2 gross margin 51%, product margin 6%); management attributes the weakness to temporary production slowdowns. » Plus sur de.investing.com

Alvotech completed a public offering of 26,066,667 common shares at $3.75 per share, including 3.4 million shares from the exercise of the over‑allotment option, raising gross proceeds of about $98 million before fees. In parallel, subscription agreements were entered into for a private placement of 17,826,667 common shares at the same price, expected to raise roughly $67 million gross and to close by June 25, 2026. After both transactions, a total of 43,893,333 common shares are expected to be issued, issued share capital would then total 390,431,480 common shares, and combined gross proceeds would be about $165 million. Alvotech intends to use the proceeds to fund biosimilar development, for working capital and general corporate purposes; the company has total debt of $1.46 billion. » Plus sur de.investing.com

Alvotech shares dropped to $3.02, marking a 52-week low, about 74% below the year high of $11.85. Over the past year the price fell 71%. For Q1 2026 the company reported EPS of -$0.09 (expectation $0.0015) and revenue of $106 million (expectation $130.89 million). Alvotech has $1.46 billion in net debt versus a market capitalization of $1.01 billion, but analyst data indicate potential undervaluation. » Plus sur de.investing.com